CALCULATE YOUR SIP RETURNS

Lupin Share Price Dips 2.99%; Posted Profit Up 38.8% YoY in Q3 FY25

Written by: Nikitha DeviUpdated on: Feb 12, 2025, 11:36 AM IST
Lupin's Q3 FY25 revenue rose to ₹38,970 million, PAT grew 38.8% YoY to ₹8,589 million. North America & India sales increased, with strong R&D investments and US FDA approvals.
Lupin Share Price Dips 2.99%; Posted Profit Up 38.8% YoY in Q3 FY25
ShareShare on 1Share on 2Share on 3Share on 4Share on 5

Lupin Limited announced its financial performance for the third quarter of the fiscal year 2025, ending December 31, 2024.

On February 12, 2025, Lupin share price opened at ₹2,079.00, up from its previous close of ₹2,067.60. At 9:38 AM, the share price of Lupin was trading at ₹2,005.85, down by 2.99% on the NSE.

Lupin’s Q3 FY 2025 Financial Highlights

For Q3 FY25, Lupin’s gross profit stood at ₹38,970 million, reflecting an increase from ₹33,538 million in Q3 FY24. The gross margin for the quarter was 69.4%. The company’s employee benefits expenses rose to ₹9,844 million, accounting for 17.5% of total sales, compared to ₹8,892 million in the same quarter last year. Manufacturing and other expenses reached ₹16,959 million, constituting 30.2% of sales, up from ₹15,601 million in Q3 FY24.

The profit before tax (PBT) for Q3 FY25 was reported at ₹10,713 million, marking a substantial year-on-year (YoY) increase of 45.5% from ₹7,361 million in Q3 FY24.

Meanwhile, the profit after tax (PAT) stood at ₹8,589 million, up 38.8% YoY from ₹6,187 million in the previous year’s quarter. However, on a quarter-on-quarter (QoQ) basis, PAT remained nearly stable compared to ₹8,595 million in Q2 FY25.

Lupin’s North America sales for the quarter reached ₹21,213 million, marking a 12.3% YoY growth from ₹18,885 million in Q3 FY24. The region accounted for 38% of the company’s global revenue. Similarly, India formulation sales increased by 12% YoY to ₹19,305 million, up from ₹17,251 million in Q3 FY24, contributing 34% to Lupin’s global sales.

As of December 31, 2024, Lupin’s operating working capital stood at ₹70,700 million, while capital expenditure for the quarter was ₹1,241 million. The company’s net debt stood at ₹1,027 million.

Research and Development

Investment in research and development (R&D) for Q3 FY25 was ₹4,344 million, representing 7.7% of total sales, up from ₹3,567 million (7.0% of sales) in the previous year.

Lupin secured six new Abbreviated New Drug Application (ANDA) approvals from the U.S. FDA, bringing its total ANDA filings to 430, with 334 approvals to date. The company also has 49 First-to-File (FTF) applications, including 17 exclusive FTF opportunities.

 

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. This does not constitute a personal recommendation/investment advice. It does not aim to influence any individual or entity to make investment decisions. Recipients should conduct their own research and assessments to form an independent opinion about investment decisions.

Investments in the securities market are subject to market risks, read all the related documents carefully before investing.

Published on: Feb 12, 2025, 9:43 AM IST

Nikitha Devi

Nikitha is a content creator with 6+ years of experience in the financial domain. Specialising in personal finance, investments, and market insights, Nikitha simplifies complex financial topics, making them accessible to readers.

Know More

We're Live on WhatsApp! Join our channel for market insights & updates

Open Free Demat Account!

Join our 2.5 Cr+ happy customers

+91
Enjoy Zero Brokerage on Equity Delivery
4.4 Cr+DOWNLOADS
Enjoy ₹0 Account Opening Charges

Get the link to download the App

Get it on Google PlayDownload on the App Store
Open Free Demat Account!
Join our 2.5 Cr+ happy customers